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ABSTRACT 
Nanosponges are tiny sponges with an average diameter below 1µm and consist of cavities filled with drug molecules. 
Lansoprazole is one of the classes of proton pump inhibitors, it reduces gastric acidity, and used in disorders such as gastric ulcer, 
duodenal ulcer and reflux oesophagitis.   In present study for extended delivery of lansoprazole at optimal concentration and to 
reduce the frequency of dosing and thus to increase patient convenience nanosponges loaded extended release tablets were 
prepared. Initially four different nanosponges formulations were prepared by solvent evaporation method and evaluated on 
various parameters. Ethyl cellulose was used as entrapping agent and dichloromethane as cross linking agent in various 
proportions and evaluated for powder flow properties, % yield, zeta potential, and in-vitro drug release characteristics. Based on 
the evaluation results, formulation NS1 was selected to prepare five extended release tablets formulations by using HPMC K30 
and chitosan as extended release polymers. All five formulations were evaluated for thickness, hardness, friability, % drug 
content and in-vitro drug release. From the results, it was found that all the evaluation results are within pharmacopoeial limits. 
From this study, we concluded feasibility of extended release of Lansoprazole through nanosponge loaded extended release 
tablets. Formulation of batch NT1, containing HPMC K30 was found to be optimum formulation. 
Keywords: Entrapment efficiency, ethyl cellulose, HPMC, in-vitro drug release, lansoprazole, nanosponges. 
Introduction 
The goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site of action in the 
body and also to achieve and it maintain the valuable plasma concentration of the drug for a particular period of 
time
1
. Nanosponge drug delivery can provide increased efficacy for topically active agents with enhanced safety, 
extended product stability and improved aesthetic properties in an efficient and novel manner
2
. 
Nanosponges are those porous polymeric delivery systems that contain small spherical particles with large porous 
surface. Nanosponge is play vital role in targeting drug delivery in a controlled manner
3
. Lipophilic and hydrophilic 
drugs are incorporated in Nanosponge
4
. These are tiny sponges with a size of about a virus. These sponges circulate 
around the body until they encounter the specific target site, stick onto the surface and begin to release the drug in a 
controlled and predictable manner
5
. 
Nanosponges can be formulated as parenteral, oral, topical or inhalational dosage forms. For oral administration, 
Nanosponge can be easily dispersed in the matrix of excipients, diluents, lubricants and anti caking agents which is 
used for the preparation of tablets or capsules formulation
6
.  
Lansoprazole is a proton pump inhibitor; it is used in the treatment of gastric ulcer, gastro oesophageal reflux 
disease (GERD), duodenal ulcer, ulcers associated with usage of Nonsteroidal anti-inflammatory drug (NSAID) and 
long term management Zollinger-Ellison syndrome
7
. Lansoprazole also exhibits antibacterial activity against 
Helicobacter pylori. Lansoprazole comes under the BCS II classification drug which has poor aqueous solubility and 
bioavailability. Regular usage of lansoprazole causes various adverse effects like abdominal pain, diarrhoea, skin 





Since oral route is preferred than other routes with respect to safety, comfort and reliability.  
So the aim of the present study was to develop extended release tablets of lansoprazole nanosponges to deliver at 
controlled rate to its absorptive site, to reduce the frequency of administration and thus to improve patient 
compliance. 
Materials and methods 
Lansoprazole was obtained from Abumec Pharmaceuticals Ltd, Kaduna State.  Ethyl cellulose, Polyvinyl alcohol, 
was obtained from AC Drugs Limited, Enugu State and Dichloromethane, HPMC K30, chitosan were obtained from 
Afrik Pharmaceuticals Plc, Awo-Omamma. Magnesium stearate, Talc and MCC pH 102 were 
procured from Avro Pharma Limited, Lagos Nigeria. 
Drug-excipient compatibility studies  
Fouriertransform infrared analysis was conducted to verify the possibility of interaction of chemical bonds between 
drug and polymers. Samples were scanned in the range from 400-4000 cm
-1
 and carbon black reference. The 




Figure 1: FTIR spectra of Lansoprazole with polymers 
 
Preparation of Lansoprazole nanosponges 
Lansoprazole nanosponges were prepared by the emulsion solvent evaporation method by the use of different 
proportions of polymers and polyvinyl alcohol
11
. Ethyl cellulose was used as entrapping agent and dichloromethane 
as cross linking agent in various proportions. The disperse phase containing Lansoprazole as a dispersing medium 
and polymer in 20ml of dichloromethane was added slowly to a definite amount of Poly vinyl alcohol in100mL of 
aqueous continuous phase with 1000 rpm stirring speed using magnetic stirrer for 2hrs. The formed nanosponges 
were collected by filtration and dried in oven at 40ºC for 24hrs and packed in vials. The preparedNanosponges 
formulations with three different polymers are listed in Table 1. 















Distilled   
water 
(ml) 
NS1  50 100 2 30 20 
NS2  100 200 3 30 20 
NS3  150 300 4 30 20 
NS4  200 400 3 30 20 
 
 
Evaluation of nanosponges micrometric properties 
Angle of repose, Bulk density, Tapped density, Hausner’s ratio and Carr’s index were determined to assess the flow 
ability of the prepared nanosponges powder. 
Determination of percentage yield 
It was calculated accurately by using the weight of final product after drying with respect to the initial total weight 
of the drug and polymer used for preparation of nanosponges
12,13
. 
        
                                       
                                 
 
 
Determination of entrapment efficiency 
Nanosponge equivalent to 100 mg of the drug were taken and then crushed into powder followed by transferred into 
a 100 ml volumetric flask consist of 10ml of methanol and the volume was made up with simulated gastric fluid of 
pH 1.2. After 24 h, the solution was filtered through Whatmann filter paper and the absorbance was measured 
spectrophotometrically after suitable dilutions
14,15
. 
Zeta Potential determination 
The zeta potential was measured for the determination of the movement velocity of the particles in an electric field 
and the particle charge. In the present work, the nanosponges was diluted 10 times with distilled water and analyzed 
by Zetasizer using Laser Doppler Micro electrophoresis (Zetasizer nano ZS, Malvern instruments Ltd., UK)
16,17
. 
In-vitro dissolution studies 
In vitro drug release was carried out by diffusion method using phosphate buffer pH 6.8 as dissolution media. 
Required quantity of sample (100 mg) was taken and then suspended in required media and then kept in the open 
ended apparatus. One end of the tube was kept open and the dialysis bag was tied (molecular weight cut off: 12–
14kDa, surface area of 22.5cm
2
) at the other end which was then submerged in a beaker containing 100ml of the 
phosphate buffer pH 7.2. Temperature of the media was kept at 37±2°C and 100 rpm speed. The samples were 
withdrawn at predetermined intervals and replaced by fresh medium simultaneously. Aliquots withdrawn were 
assayed at each time interval for the drug released at λ max of 236 nm using UV‐ Visible spectrophotometer18,19. 
Formulation of Lansoprazole nanosponge loaded extended release tablets 
 
From the results of evaluation studies of nanosponges, the formulation NS1 was selected and Optimized for 
preparation of nanosponge extended release tablets.  Five different extended release tablets formulations were 
prepared with varying concentrations of polymers by direct compression method
20
. HPMC K30 and chitosan were 
used as polymers, talc as lubricant and magnesium stearate acts as glidant and microcrystalline cellulose was used as 
a directly compressible binder.  Compositions of different formulations were given in Table 3.  
Lansoprazole nanosponges and all other ingredients were individually passed through sieve number #60 and all the 
ingredients were mixed thoroughly by triturating up to 15 min followed by lubricated with talc. Finally the 
lubricated mixture was subjected to direct compression by using RIMEK rotary tablet punching machine. 





























NS1 0.53±0.12 0.58±0.09 8.61±0.13 1.09±0.06 240.37±0.09 97.35±0.08 89.43±0.09 -6.1 
NS2 0.49±0.08 0.54±0.11 9.25±0.08 1.04±0.05 245.59±0.06 81.43±0.12 86.25±0.13 -5.2 
NS3 0.51±0.06 0.56±0.09 8.92±0.06 1.09±0.03 242.31±0.12 85.41±0.09 81.42±0.08 -5.6 
NS4 0.55±0.04 0.60±0.06 8.33±0.14 1.08±0.04 220.43±0.31 90.37±0.06 85.43±0.05 -5.9 
 
 
Evaluation of tablets 
Post compression studies 
The manufactured nanosponge loaded tablets were subjected to weight variation, hardness (Pfizer hardness tester), 




Ten tablets were weighed, finely powdered andtriturate equivalent to 10 mg of the drug was 
accurately weighed, dissolved in pH 1.2 buffer and volume was made up to 100 ml with the same buffer. Further 




In-vitro drug release studies of tablets 
900ml of 0.1N HCl was placed in vessel and the USP apparatus-II (Paddle Method) was assembled. The medium 
was allowed to equilibrate to temperature of 37±0.5°C. Nanosponge loaded tablet was placed in the vessel and 
operated at 50 rpm. Then the medium was replaced with pH 6.8 phosphate buffer and continued up to 10 h at 50 
rpm. At definite time intervals, 5 ml of the receptor fluid was withdrawn and same volume was replaced with fresh 
medium. The withdrawn fluid was filtered, suitably diluted and analyzed using UV-spectrophotometer
27
. 






















NT1 200 75 - 5 3 60 
NT2 200 50 - 5 3 60 
NT3 200 25 20 5 3 60 
NT4 200 - 50 5 3 60 
NT5 200 - 75 5 3 60 
 
Figure 2: Dissolution profiles of nanosponges formulations 



















NT1 336±0.38 4.8±0.09 3.49±0.09 0.48±0.09 
 
NT2 318±0.45 4.7±0.12 3.28±0.11 0.33±0.12 
NT3 310±0.61 4.2±0.13 3.31±0.05 0.46±0.15 
NT4 318±0.28 4.9±0.25 3.48±0.18 0.42±0.08 
NT5 342±0.39 4.1±0.09 3.86±0.08 0.41±0.14 








Results and discussion 
The present study was aimed for developing Lansoprazole nanosponge loaded extended release tablets using various 
polymers and excipients. In present study four nanosponges formulations were prepared. Excipients compatibility 
studies were performed by FT-IR spectroscopy (Figure 1). No significant shifting of the peaks, so polymers used in 
the study are suitable for the development of Lansoprazole nanosponge formulations. 
Percentage yield value of nanosponges was found to be the best for NS1 i.e. 97.35±0.08. It was observed that as the 
polymer ratio in the formulation increases, the percentage yield also increases. The low percentage yield in some 
formulations may be due to wastage of the drug-polymer solution. 
The % drug entrapment efficiency of the nanosponges was found to be best for the formulation NS1 and it was 
ranged from 68.86±0.10 to 88.66±0.5 and the results indicated that the ethyl cellulose concentration is directly 
proportional to the entrapment efficiency but polyvinyl alcohol concentration is indirectly proportional to the 
entrapment efficiency which is due to the low solubility of polymer in aqueous phase (Table 2). The surface charge 
of nanosponges was determined by zeta potential and it was found to be in the range of 5.2-6.1mv (±30mv). The in-
vitro drug release studies of Lansoprazole nanosponges were performed for all the 4 formulations by using USP 
Type-II i.e. paddle. All the formulations showed drug release for a period of 8 h (Figure 2). Among all the 
formulations NS1 has shown highest percentage of drug release i.e., 98.35% at the end of 8 h.From the results of 
evaluation parameters, formulation NS1 has shown acceptable results and hence, it was selected for further studies.  
Five different Lansoprazole nanosponge loaded extended release tablets were prepared using HPMC K30 and 
chitosan and evaluated for flow properties and in-vitro drug release studies.  
The powder blend was subjected to pre-compression studies and obtained results were complied with the 
pharmacopoeial limits (Table 4). The in-vitro drug dissolution studies of nanosponge loaded extended release tablets 
were performed by taking USP dissolution apparatus-II. In 10 hrs studies, the cumulative percentage drug release 
was found to be in the range of 42.58±0.09 to 74.81±0.12. Maximum release was shown by the formulations of 
batch NT1. This may be due hydrophilic nature of HPMC. 
 
Conclusion 
In present study nanosponge loaded extended release tablets of Lansoprazole showed extended drug release for 
about 10 h. On the basis of different parameters it is concluded that the nanosponge formulations of batch NS1 and 
nanosponges loaded extended release tablets of batch NT1 are the optimum formulations. 
Study concluded that prolonged drug release and nanosponges loaded extended release tablets of Lansoprazole are 
suitable option for dose reduction, reduced frequency of administration and avoiding related systemic side effects. 
However further in-vivo study is needed for further estimation of importance of these formulations.  
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